γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Despite promising objective response rates, most patients relapse, and low levels of BCMA on a subset of tumor cells has been suggested as a probable escape mechanism....
Saved in:
| Published in | Blood Vol. 134; no. 19; pp. 1585 - 1597 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
07.11.2019
American Society of Hematology |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Despite promising objective response rates, most patients relapse, and low levels of BCMA on a subset of tumor cells has been suggested as a probable escape mechanism. BCMA is actively cleaved from the tumor cell surface by the ubiquitous multisubunit γ-secretase (GS) complex, which reduces ligand density on tumor cells for CAR T-cell recognition and releases a soluble BCMA (sBCMA) fragment capable of inhibiting CAR T-cell function. Sufficient sBCMA can accumulate in the bone marrow of MM patients to inhibit CAR T-cell recognition of tumor cells, and potentially limit efficacy of BCMA-directed adoptive T-cell therapy. We investigated whether blocking BCMA cleavage by small-molecule GS inhibitors (GSIs) could augment BCMA-targeted CAR T-cell therapy. We found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion, concurrently decreased sBCMA concentrations, and improved tumor recognition by CAR T cells in vitro. GSI treatment of MM tumor-bearing NOD/SCID/γc−/− mice increased BCMA expression on tumor cells, decreased sBCMA in peripheral blood, and improved antitumor efficacy of BCMA-targeted CAR T-cell therapy. Importantly, short-term GSI administration to MM patients markedly increases the percentage of BCMA+ tumor cells, and the levels of BCMA surface expression in vivo. Based on these data, a US Food and Drug Administration (FDA)-approved clinical trial has been initiated, combining GSI with concurrent BCMA CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT03502577.
•Small-molecule GSIs increase BCMA surface expression on myeloma cells, resulting in enhanced CAR T-cell efficacy.
[Display omitted] |
|---|---|
| AbstractList | B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Despite promising objective response rates, most patients relapse, and low levels of BCMA on a subset of tumor cells has been suggested as a probable escape mechanism. BCMA is actively cleaved from the tumor cell surface by the ubiquitous multisubunit γ-secretase (GS) complex, which reduces ligand density on tumor cells for CAR T-cell recognition and releases a soluble BCMA (sBCMA) fragment capable of inhibiting CAR T-cell function. Sufficient sBCMA can accumulate in the bone marrow of MM patients to inhibit CAR T-cell recognition of tumor cells, and potentially limit efficacy of BCMA-directed adoptive T-cell therapy. We investigated whether blocking BCMA cleavage by small-molecule GS inhibitors (GSIs) could augment BCMA-targeted CAR T-cell therapy. We found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion, concurrently decreased sBCMA concentrations, and improved tumor recognition by CAR T cells in vitro. GSI treatment of MM tumor-bearing NOD/SCID/γc-/- mice increased BCMA expression on tumor cells, decreased sBCMA in peripheral blood, and improved antitumor efficacy of BCMA-targeted CAR T-cell therapy. Importantly, short-term GSI administration to MM patients markedly increases the percentage of BCMA+ tumor cells, and the levels of BCMA surface expression in vivo. Based on these data, a US Food and Drug Administration (FDA)-approved clinical trial has been initiated, combining GSI with concurrent BCMA CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT03502577. Small-molecule GSIs increase BCMA surface expression on myeloma cells, resulting in enhanced CAR T-cell efficacy. B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Despite promising objective response rates, most patients relapse, and low levels of BCMA on a subset of tumor cells has been suggested as a probable escape mechanism. BCMA is actively cleaved from the tumor cell surface by the ubiquitous multisubunit γ-secretase (GS) complex, which reduces ligand density on tumor cells for CAR T-cell recognition and releases a soluble BCMA (sBCMA) fragment capable of inhibiting CAR T-cell function. Sufficient sBCMA can accumulate in the bone marrow of MM patients to inhibit CAR T-cell recognition of tumor cells, and potentially limit efficacy of BCMA-directed adoptive T-cell therapy. We investigated whether blocking BCMA cleavage by small-molecule GS inhibitors (GSIs) could augment BCMA-targeted CAR T-cell therapy. We found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion, concurrently decreased sBCMA concentrations, and improved tumor recognition by CAR T cells in vitro. GSI treatment of MM tumor-bearing NOD/SCID/γc −/− mice increased BCMA expression on tumor cells, decreased sBCMA in peripheral blood, and improved antitumor efficacy of BCMA-targeted CAR T-cell therapy. Importantly, short-term GSI administration to MM patients markedly increases the percentage of BCMA + tumor cells, and the levels of BCMA surface expression in vivo. Based on these data, a US Food and Drug Administration (FDA)-approved clinical trial has been initiated, combining GSI with concurrent BCMA CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT03502577. B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Despite promising objective response rates, most patients relapse, and low levels of BCMA on a subset of tumor cells has been suggested as a probable escape mechanism. BCMA is actively cleaved from the tumor cell surface by the ubiquitous multisubunit γ-secretase (GS) complex, which reduces ligand density on tumor cells for CAR T-cell recognition and releases a soluble BCMA (sBCMA) fragment capable of inhibiting CAR T-cell function. Sufficient sBCMA can accumulate in the bone marrow of MM patients to inhibit CAR T-cell recognition of tumor cells, and potentially limit efficacy of BCMA-directed adoptive T-cell therapy. We investigated whether blocking BCMA cleavage by small-molecule GS inhibitors (GSIs) could augment BCMA-targeted CAR T-cell therapy. We found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion, concurrently decreased sBCMA concentrations, and improved tumor recognition by CAR T cells in vitro. GSI treatment of MM tumor-bearing NOD/SCID/γc−/− mice increased BCMA expression on tumor cells, decreased sBCMA in peripheral blood, and improved antitumor efficacy of BCMA-targeted CAR T-cell therapy. Importantly, short-term GSI administration to MM patients markedly increases the percentage of BCMA+ tumor cells, and the levels of BCMA surface expression in vivo. Based on these data, a US Food and Drug Administration (FDA)-approved clinical trial has been initiated, combining GSI with concurrent BCMA CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT03502577. •Small-molecule GSIs increase BCMA surface expression on myeloma cells, resulting in enhanced CAR T-cell efficacy. [Display omitted] B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Despite promising objective response rates, most patients relapse, and low levels of BCMA on a subset of tumor cells has been suggested as a probable escape mechanism. BCMA is actively cleaved from the tumor cell surface by the ubiquitous multisubunit γ-secretase (GS) complex, which reduces ligand density on tumor cells for CAR T-cell recognition and releases a soluble BCMA (sBCMA) fragment capable of inhibiting CAR T-cell function. Sufficient sBCMA can accumulate in the bone marrow of MM patients to inhibit CAR T-cell recognition of tumor cells, and potentially limit efficacy of BCMA-directed adoptive T-cell therapy. We investigated whether blocking BCMA cleavage by small-molecule GS inhibitors (GSIs) could augment BCMA-targeted CAR T-cell therapy. We found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion, concurrently decreased sBCMA concentrations, and improved tumor recognition by CAR T cells in vitro. GSI treatment of MM tumor-bearing NOD/SCID/γc-/- mice increased BCMA expression on tumor cells, decreased sBCMA in peripheral blood, and improved antitumor efficacy of BCMA-targeted CAR T-cell therapy. Importantly, short-term GSI administration to MM patients markedly increases the percentage of BCMA+ tumor cells, and the levels of BCMA surface expression in vivo. Based on these data, a US Food and Drug Administration (FDA)-approved clinical trial has been initiated, combining GSI with concurrent BCMA CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT03502577.B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Despite promising objective response rates, most patients relapse, and low levels of BCMA on a subset of tumor cells has been suggested as a probable escape mechanism. BCMA is actively cleaved from the tumor cell surface by the ubiquitous multisubunit γ-secretase (GS) complex, which reduces ligand density on tumor cells for CAR T-cell recognition and releases a soluble BCMA (sBCMA) fragment capable of inhibiting CAR T-cell function. Sufficient sBCMA can accumulate in the bone marrow of MM patients to inhibit CAR T-cell recognition of tumor cells, and potentially limit efficacy of BCMA-directed adoptive T-cell therapy. We investigated whether blocking BCMA cleavage by small-molecule GS inhibitors (GSIs) could augment BCMA-targeted CAR T-cell therapy. We found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion, concurrently decreased sBCMA concentrations, and improved tumor recognition by CAR T cells in vitro. GSI treatment of MM tumor-bearing NOD/SCID/γc-/- mice increased BCMA expression on tumor cells, decreased sBCMA in peripheral blood, and improved antitumor efficacy of BCMA-targeted CAR T-cell therapy. Importantly, short-term GSI administration to MM patients markedly increases the percentage of BCMA+ tumor cells, and the levels of BCMA surface expression in vivo. Based on these data, a US Food and Drug Administration (FDA)-approved clinical trial has been initiated, combining GSI with concurrent BCMA CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT03502577. Despite notably high response rates to B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells in multiple myeloma, few patients have a sustained, very good partial or complete response. This article presents a novel strategy to increase the efficacy of BCMA-directed CAR T-cell therapy and shows that γ-secretase inhibitors improve the efficacy of BCMA CAR T cells by increasing BCMA expression and reducing soluble BCMA. |
| Author | Rajan, Anusha Wood, Brent L. Voutsinas, Jenna M. Hudecek, Michael Riddell, Stanley R. Patel, Bharvin K.R. Hill, Tyler Wu, Qian Green, Damian J. Salter, Alexander I. Kelliher, Jessica Comstock, Melissa L. Cowan, Andrew J. Cole, Gabriel O. Liu, Lingfeng Pont, Margot J. Abbott, Joe J. |
| Author_xml | – sequence: 1 givenname: Margot J. orcidid: 0000-0002-5934-9990 surname: Pont fullname: Pont, Margot J. email: sriddell@fredhutch.org organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 2 givenname: Tyler orcidid: 0000-0002-9192-8327 surname: Hill fullname: Hill, Tyler organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 3 givenname: Gabriel O. orcidid: 0000-0003-0135-2406 surname: Cole fullname: Cole, Gabriel O. organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 4 givenname: Joe J. surname: Abbott fullname: Abbott, Joe J. organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 5 givenname: Jessica surname: Kelliher fullname: Kelliher, Jessica organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 6 givenname: Alexander I. orcidid: 0000-0003-3820-0895 surname: Salter fullname: Salter, Alexander I. organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 7 givenname: Michael surname: Hudecek fullname: Hudecek, Michael organization: Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany – sequence: 8 givenname: Melissa L. surname: Comstock fullname: Comstock, Melissa L. organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 9 givenname: Anusha orcidid: 0000-0002-0036-4301 surname: Rajan fullname: Rajan, Anusha organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 10 givenname: Bharvin K.R. surname: Patel fullname: Patel, Bharvin K.R. organization: Eli Lilly and Company, Indianapolis, IN – sequence: 11 givenname: Jenna M. surname: Voutsinas fullname: Voutsinas, Jenna M. organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 12 givenname: Qian surname: Wu fullname: Wu, Qian organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 13 givenname: Lingfeng orcidid: 0000-0001-6182-9822 surname: Liu fullname: Liu, Lingfeng organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 14 givenname: Andrew J. surname: Cowan fullname: Cowan, Andrew J. organization: Department of Medicine, University of Washington, Seattle, WA – sequence: 15 givenname: Brent L. surname: Wood fullname: Wood, Brent L. organization: Department of Medicine, University of Washington, Seattle, WA – sequence: 16 givenname: Damian J. orcidid: 0000-0003-0477-1446 surname: Green fullname: Green, Damian J. organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA – sequence: 17 givenname: Stanley R. surname: Riddell fullname: Riddell, Stanley R. organization: Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31558469$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1UU1v1DAQtVAR3RbunJCPXNL6I04cDkjtCihSEQfK2bKdcdcosVPbW2l_F_-D34SXLQUOzMUzb9482_NO0FGIARB6SckZpZKdmynG8YwROpAagjxBKyqYbAhh5AitKtY17dDTY3SS8zdCaMuZeIaOORVCtt2wQnc_vjdfwCYoOgP2YeONLz6GmlawYhmDc95qu8PR4cv1p4smL2B9xbDd-BlSTXQo_hYCTmBhKTHhG2xhmnJVwfN2Kn6ZAM87mOKsn6OnTk8ZXjycp-jr-3c366vm-vOHj-uL68a2PS0NM-PQi5ZLLkbZcyM70klhuTXCWUmGkVNDOetb3dLeGaC8r1ztNDjDoZan6O1Bd9maGUYLoSQ9qSX5WaeditqrfzvBb9RtvFed7Cmne4HXDwIp3m0hFzX7vP-WDhC3WTE2DJR3nAyVSg5Um2LOCdzjNZSovVPql1Pqj1N15NXfz3sc-G1NJbw5EKAu6d5DUtl6CBZGX9dc1Bj9_9V_AvT6qAI |
| CitedBy_id | crossref_primary_10_1016_j_bulcan_2021_09_005 crossref_primary_10_1038_s41417_024_00750_2 crossref_primary_10_1097_PPO_0000000000000506 crossref_primary_10_1177_20406207211019622 crossref_primary_10_1016_S1470_2045_23_00246_2 crossref_primary_10_1111_bjh_19222 crossref_primary_10_3390_cancers12041045 crossref_primary_10_1016_j_semcdb_2020_05_019 crossref_primary_10_1186_s12935_022_02778_6 crossref_primary_10_3390_cancers13081955 crossref_primary_10_1080_14737140_2020_1708721 crossref_primary_10_1038_s41467_024_47801_8 crossref_primary_10_1016_j_ccell_2022_04_001 crossref_primary_10_1158_1078_0432_CCR_21_3874 crossref_primary_10_1177_09612033231164633 crossref_primary_10_3390_hemato2010001 crossref_primary_10_1136_jitc_2022_005091 crossref_primary_10_1136_jitc_2022_005403 crossref_primary_10_1182_bloodadvances_2023010410 crossref_primary_10_1016_j_canlet_2022_215949 crossref_primary_10_3390_cancers12051075 crossref_primary_10_3389_fimmu_2022_927153 crossref_primary_10_1158_2643_3230_BCD_21_0073 crossref_primary_10_1007_s40487_022_00186_4 crossref_primary_10_1182_blood_2019004469 crossref_primary_10_1186_s13045_023_01492_8 crossref_primary_10_3324_haematol_2022_281339 crossref_primary_10_1038_s41375_022_01539_8 crossref_primary_10_1080_10428194_2023_2284088 crossref_primary_10_1097_CCO_0000000000000667 crossref_primary_10_3390_cancers12061473 crossref_primary_10_1097_PPO_0000000000000525 crossref_primary_10_3389_fimmu_2020_00501 crossref_primary_10_1038_s41467_023_39395_4 crossref_primary_10_3390_cancers13236136 crossref_primary_10_3390_jcm11092513 crossref_primary_10_1172_JCI129205 crossref_primary_10_1097_CM9_0000000000002476 crossref_primary_10_3390_jcm9093022 crossref_primary_10_1080_17474086_2021_1909469 crossref_primary_10_1111_imr_13015 crossref_primary_10_1007_s12185_023_03579_x crossref_primary_10_2147_BLCTT_S327016 crossref_primary_10_3389_fimmu_2022_1050522 crossref_primary_10_1177_2040620720979813 crossref_primary_10_1016_j_drup_2024_101082 crossref_primary_10_1080_17474086_2020_1756258 crossref_primary_10_1016_j_clml_2021_12_003 crossref_primary_10_1136_jitc_2020_000734 crossref_primary_10_33590_emjhematol_20_00231 crossref_primary_10_3390_cells9061503 crossref_primary_10_1158_2159_8290_CD_20_0242 crossref_primary_10_3390_genes14051008 crossref_primary_10_3324_haematol_2020_276402 crossref_primary_10_3389_fonc_2020_606368 crossref_primary_10_1056_NEJMc2211969 crossref_primary_10_1038_s41573_023_00807_1 crossref_primary_10_1038_s41392_023_01702_2 crossref_primary_10_1002_med_21876 crossref_primary_10_1158_2767_9764_CRC_21_0157 crossref_primary_10_1186_s40779_021_00302_x crossref_primary_10_1097_CCO_0000000000000653 crossref_primary_10_1007_s11427_020_1713_9 crossref_primary_10_1158_0008_5472_CAN_21_0524 crossref_primary_10_3324_haematol_2020_266841 crossref_primary_10_1038_s41409_020_01023_w crossref_primary_10_1016_j_hoc_2023_05_008 crossref_primary_10_1111_ejh_14074 crossref_primary_10_1111_sji_12910 crossref_primary_10_1038_s41408_020_0337_y crossref_primary_10_21320_2500_2139_2023_16_1_1_13 crossref_primary_10_3390_cancers13092018 crossref_primary_10_3390_cells9030601 crossref_primary_10_1038_s41571_020_0427_6 crossref_primary_10_1080_2162402X_2022_2111904 crossref_primary_10_1097_CCO_0000000000000664 crossref_primary_10_1182_bloodadvances_2022007625 crossref_primary_10_3389_fimmu_2022_1027385 crossref_primary_10_3389_fonc_2020_01243 crossref_primary_10_1016_j_cell_2020_03_001 crossref_primary_10_3390_curroncol29110705 crossref_primary_10_18632_oncotarget_28538 crossref_primary_10_1097_CM9_0000000000002549 crossref_primary_10_1016_j_beha_2020_101141 crossref_primary_10_1016_j_jtct_2023_04_007 crossref_primary_10_1158_2643_3230_BCD_20_0227 crossref_primary_10_1080_10428194_2022_2133540 crossref_primary_10_1039_D0MD00221F crossref_primary_10_1136_bmj_m3176 crossref_primary_10_1158_1078_0432_CCR_23_3759 crossref_primary_10_3389_fimmu_2023_1101495 crossref_primary_10_1002_jha2_357 crossref_primary_10_1097_MOH_0000000000000614 crossref_primary_10_1002_ajh_27225 crossref_primary_10_1038_s43018_021_00241_5 crossref_primary_10_3389_fimmu_2020_00776 crossref_primary_10_1158_2643_3230_BCD_20_0122 crossref_primary_10_3389_fimmu_2022_957157 crossref_primary_10_1038_s41408_021_00469_5 crossref_primary_10_3389_fimmu_2022_839097 crossref_primary_10_1038_s41571_020_0356_4 crossref_primary_10_1146_annurev_med_050522_033815 crossref_primary_10_1158_2767_9764_CRC_22_0083 crossref_primary_10_1016_j_tranon_2022_101459 crossref_primary_10_1097_HS9_0000000000000575 crossref_primary_10_17925_OHR_2022_18_1_59 crossref_primary_10_3389_fimmu_2024_1383136 crossref_primary_10_1056_NEJMc2105069 crossref_primary_10_1038_s41586_023_05707_3 crossref_primary_10_1016_j_coi_2021_06_015 crossref_primary_10_3390_ijms25115634 crossref_primary_10_1038_s41408_024_00986_z crossref_primary_10_1177_1758835920962963 crossref_primary_10_3324_haematol_2022_282053 crossref_primary_10_3389_fimmu_2022_954235 crossref_primary_10_1002_ajh_26750 crossref_primary_10_1016_j_coi_2021_02_010 crossref_primary_10_17650_1818_8346_2022_17_1_43_52 crossref_primary_10_1186_s12943_022_01669_8 crossref_primary_10_3389_fphar_2021_720692 crossref_primary_10_1016_j_jchromb_2021_122944 crossref_primary_10_1002_ajh_26753 crossref_primary_10_3390_hemato2040043 crossref_primary_10_3390_cells11030410 crossref_primary_10_15252_emmm_202216084 crossref_primary_10_1111_ejh_14145 crossref_primary_10_1186_s13045_022_01249_9 crossref_primary_10_3390_pharmaceutics12020194 crossref_primary_10_1055_a_1243_1681 crossref_primary_10_1016_j_jtct_2022_03_005 crossref_primary_10_1182_bloodadvances_2019001346 crossref_primary_10_1200_EDBK_389860 crossref_primary_10_1007_s00277_023_05444_7 crossref_primary_10_1158_1078_0432_CCR_20_3600 crossref_primary_10_1186_s13045_020_00962_7 crossref_primary_10_1158_2159_8290_CD_21_1683 crossref_primary_10_1038_s41467_022_31810_6 crossref_primary_10_1182_bloodadvances_2022009387 crossref_primary_10_1007_s12254_022_00825_6 crossref_primary_10_1016_j_bbmt_2020_06_011 crossref_primary_10_1186_s12967_023_04655_w crossref_primary_10_1002_acg2_93 crossref_primary_10_1182_blood_2021015144 crossref_primary_10_3390_cancers15082240 crossref_primary_10_2217_fon_2020_1269 crossref_primary_10_1002_JLB_4A1221_743R crossref_primary_10_1007_s00262_022_03163_y crossref_primary_10_1200_JCO_20_01738 crossref_primary_10_1038_s41434_021_00254_w crossref_primary_10_1016_j_copbio_2019_11_020 crossref_primary_10_1182_blood_2019004176 crossref_primary_10_1007_s11523_021_00821_6 crossref_primary_10_3389_fimmu_2021_724411 crossref_primary_10_1038_s41571_023_00754_1 crossref_primary_10_1016_j_ajpath_2024_04_002 crossref_primary_10_3389_fimmu_2022_825979 crossref_primary_10_1038_s41568_020_00323_z crossref_primary_10_1002_JLB_1MR0520_746R crossref_primary_10_1080_14656566_2022_2101362 crossref_primary_10_1007_s11684_021_0904_z crossref_primary_10_1016_j_blre_2020_100695 crossref_primary_10_3390_cells12232748 crossref_primary_10_3389_fimmu_2022_886429 crossref_primary_10_1016_j_actbio_2022_02_028 crossref_primary_10_3322_caac_21771 crossref_primary_10_3389_fimmu_2022_1019115 crossref_primary_10_1186_s12967_022_03285_y crossref_primary_10_1186_s13045_022_01296_2 crossref_primary_10_1016_j_trecan_2024_06_002 crossref_primary_10_3390_vaccines11111721 crossref_primary_10_1007_s40265_022_01793_1 crossref_primary_10_3389_fimmu_2020_01128 crossref_primary_10_3390_cancers11122009 crossref_primary_10_1080_14712598_2020_1738378 crossref_primary_10_3390_cancers14174082 crossref_primary_10_2217_fon_2021_1090 crossref_primary_10_3390_ijms21155192 crossref_primary_10_1016_j_yexcr_2021_112971 crossref_primary_10_2147_ITT_S306103 crossref_primary_10_1016_j_pharmthera_2021_108007 crossref_primary_10_3389_fonc_2022_1070353 crossref_primary_10_3389_fphar_2023_1149138 crossref_primary_10_1016_j_intimp_2020_107072 crossref_primary_10_1007_s11899_021_00639_z crossref_primary_10_3389_fonc_2021_607291 crossref_primary_10_1016_S1470_2045_23_00283_8 crossref_primary_10_1016_j_modpat_2022_100050 crossref_primary_10_1038_s41408_022_00716_3 crossref_primary_10_3389_fonc_2022_925818 crossref_primary_10_3389_fimmu_2021_632937 crossref_primary_10_1182_hematology_2020000111 crossref_primary_10_1016_j_jcyt_2024_01_011 crossref_primary_10_1007_s11864_023_01049_4 crossref_primary_10_3390_cancers15061819 crossref_primary_10_1038_s41571_024_00913_y crossref_primary_10_1371_journal_pone_0301175 crossref_primary_10_3390_cancers11122024 crossref_primary_10_4049_jimmunol_2101107 crossref_primary_10_1080_10428194_2021_1913146 crossref_primary_10_1158_1078_0432_CCR_21_1546 crossref_primary_10_1080_10428194_2023_2276676 |
| Cites_doi | 10.1016/j.canlet.2015.07.048 10.1158/2326-6066.CIR-14-0127 10.1038/ncomms8333 10.1158/2159-8290.CD-15-1020 10.1182/blood-2016-01-631200 10.1182/blood-2011-02-337360 10.1200/JCO.2011.36.8282 10.1016/j.bbamem.2013.06.005 10.1016/j.ymthe.2017.06.008 10.1182/blood-2013-10-535088 10.1126/scisignal.aat6753 10.1182/blood-2015-06-653261 10.1056/NEJMra1011442 10.1016/S1074-7613(04)00081-0 10.1200/JCO.2018.77.8084 10.3324/haematol.2016.150896 10.1182/blood-2009-08-238196 10.1021/jacs.5b01876 10.1016/0022-1759(90)90210-M 10.1084/jem.192.1.129 10.1158/1535-7163.MCT-06-0254 10.1111/bjh.15116 10.1056/NEJMoa1215134 10.1084/jem.192.11.1677 10.1182/blood-2003-06-1984 10.1093/annonc/mdy244 10.1038/nm.3910 10.1038/leu.2011.196 10.1126/scitranslmed.3005930 10.1016/j.ccell.2017.02.002 10.1200/JCO.2005.04.5807 10.1158/1078-0432.CCR-15-2224 10.1200/JCO.2017.72.8519 10.1182/blood-2016-04-711903 10.1172/JCI126397 10.1056/NEJMoa022340 10.1182/blood-2017-04-778423 10.1007/s10549-012-2075-8 10.1126/scitranslmed.aaa0984 10.1056/NEJM199607113350204 10.1084/jem.20031330 10.1182/blood-2003-06-2043 10.1038/s41591-018-0041-7 10.1038/nbt.3461 10.1038/leu.2017.57 10.1016/j.bbmt.2016.07.007 10.1080/15384047.2016.1156261 10.1126/scitranslmed.3002842 10.1158/1078-0432.CCR-12-2422 10.1172/JCI18025 10.1056/NEJMoa1817226 10.1200/JCO.2014.56.2025 10.1126/scitranslmed.aaf8621 10.1016/j.leukres.2018.07.015 10.1038/s41591-018-0036-4 10.1158/1078-0432.CCR-13-0330 10.1159/000082107 10.1038/leu.2017.329 10.1056/NEJMoa1407222 10.1038/nm.4441 10.4049/jimmunol.1402346 |
| ContentType | Journal Article |
| Copyright | 2019 American Society of Hematology 2019 by The American Society of Hematology. 2019 by The American Society of Hematology 2019 |
| Copyright_xml | – notice: 2019 American Society of Hematology – notice: 2019 by The American Society of Hematology. – notice: 2019 by The American Society of Hematology 2019 |
| DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1182/blood.2019000050 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| EndPage | 1597 |
| ExternalDocumentID | 10_1182_blood_2019000050 31558469 S0006497120739935 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P01 CA018029 – fundername: NCI NIH HHS grantid: R01 CA136551 – fundername: ; |
| GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. 6J9 AAEDW AAFTH AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ 0SF AALRI ADVLN AFETI AITUG AKRWK CGR CUY CVF ECM EIF H13 NPM AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c471t-2bd97543835d873b860685c3cb5fc809d31b13274a417fbe137383afaefb3ee13 |
| IEDL.DBID | ABVKL |
| ISSN | 0006-4971 1528-0020 |
| IngestDate | Tue Sep 17 21:21:03 EDT 2024 Fri Sep 06 20:23:51 EDT 2024 Thu Sep 12 20:11:36 EDT 2024 Wed Oct 02 05:29:12 EDT 2024 Fri Feb 23 02:43:30 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 19 |
| Language | English |
| License | This article is made available under the Elsevier license. 2019 by The American Society of Hematology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c471t-2bd97543835d873b860685c3cb5fc809d31b13274a417fbe137383afaefb3ee13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 D.J.G. and S.R.R. share authorship. |
| ORCID | 0000-0002-5934-9990 0000-0001-6182-9822 0000-0003-3820-0895 0000-0002-0036-4301 0000-0003-0135-2406 0000-0003-0477-1446 0000-0002-9192-8327 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0006497120739935 |
| PMID | 31558469 |
| PQID | 2299136309 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6871311 proquest_miscellaneous_2299136309 crossref_primary_10_1182_blood_2019000050 pubmed_primary_31558469 elsevier_sciencedirect_doi_10_1182_blood_2019000050 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-11-07 2019-11-7 20191107 |
| PublicationDateYYYYMMDD | 2019-11-07 |
| PublicationDate_xml | – month: 11 year: 2019 text: 2019-11-07 day: 07 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Washington, DC |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2019 |
| Publisher | Elsevier Inc American Society of Hematology |
| Publisher_xml | – name: Elsevier Inc – name: American Society of Hematology |
| References | Massard, Azaro, Soria (bib46) 2018; 29 Child, Morgan, Davies, Medical Research Council Adult Leukaemia Working Party (bib4) 2003; 348 Fry, Shah, Orentas (bib32) 2018; 24 Harousseau, Attal, Divine (bib5) 1995; 13 Varga, Laubach, Anderson, Richardson (bib57) 2018; 181 Sanchez, Gillespie, Tang (bib58) 2016; 22 Lyu, Cheung, Hittelman, Marks, Aguiar, Rosenblum (bib54) 2007; 6 Jelinek, Darce (bib23) 2005; 8 Moreaux, Legouffe, Jourdan (bib25) 2004; 103 Sotillo, Barrett, Black (bib49) 2015; 5 Cohen, Garfall, Stadtmauer (bib28) 2019; 129 O'Connor, Raman, Erickson (bib19) 2004; 199 Ali, Shi, Maric (bib26) 2016; 128 Laurent, Hoffmann, Kuhn (bib33) 2015; 6 Salter, Ivey, Kennedy (bib36) 2018; 11 Attal, Harousseau, Stoppa (bib1) 1996; 335 Kumar, Lee, Lahuerta, International Myeloma Working Group (bib10) 2012; 26 Giavridis, van der Stegen, Eyquem, Hamieh, Piersigilli, Sadelain (bib61) 2018; 24 Golde, Koo, Felsenstein, Osborne, Miele (bib34) 2013; 1828 Tai, Mayes, Acharya (bib56) 2014; 123 Debeb, Cohen, Boley (bib52) 2012; 134 Rennert, Schneider, Cachero (bib22) 2000; 192 Bladé, Rosiñol, Cibeira, Rovira, Carreras (bib3) 2010; 115 Raje, Berdeja, Lin (bib29) 2019; 380 Chim, Kumar, Orlowski (bib8) 2018; 32 Grupp, Kalos, Barrett (bib30) 2013; 368 Salem, Maric, Yuan (bib45) 2018; 71 Pisklakova, Grigson, Ozerova, Chen, Sullivan, Nefedova (bib60) 2016; 17 Kalos, Levine, Porter (bib15) 2011; 3 Seckinger, Delgado, Moser (bib20) 2017; 31 Ramadoss, Schulman, Choi (bib55) 2015; 137 Kochenderfer, Dudley, Kassim (bib17) 2015; 33 Avery, Kalled, Ellyard (bib18) 2003; 112 Barlogie, Kyle, Anderson (bib2) 2006; 24 Turtle, Hanafi, Berger (bib14) 2016; 8 Thompson, Schneider, Kalled (bib21) 2000; 192 Watanabe, Terakura, Martens (bib48) 2015; 194 Sommermeyer, Hill, Shamah (bib43) 2017; 31 Riddell, Greenberg (bib44) 1990; 128 Gogishvili, Danhof, Prommersberger (bib39) 2017; 130 Maude, Frey, Shaw (bib13) 2014; 371 O'Rourke, Nasrallah, Desai (bib31) 2017; 9 Carpenter, Evbuomwan, Pittaluga (bib40) 2013; 19 Brentjens, Davila, Riviere (bib12) 2013; 5 Yuan, Wu, Xu (bib35) 2015; 369 Hudecek, Sommermeyer, Kosasih (bib38) 2015; 3 Eagar, Tang, Wolfe, He, Pear, Bluestone (bib51) 2004; 20 Lonial, Boise, Kaufman (bib9) 2015; 126 Norelli, Camisa, Barbiera (bib62) 2018; 24 Brudno, Maric, Hartman (bib27) 2018; 36 Rapoport, Stadtmauer, Binder-Scholl (bib50) 2015; 21 Turtle, Hay, Hanafi (bib16) 2017; 35 Hudecek, Lupo-Stanghellini, Kosasih (bib37) 2013; 19 Sonneveld, Avet-Loiseau, Lonial (bib7) 2016; 127 Ghermezi, Li, Vardanyan (bib47) 2017; 102 Walker, Majzner, Zhang (bib53) 2017; 25 Novak, Darce, Arendt (bib24) 2004; 103 Tolcher, Messersmith, Mikulski (bib59) 2012; 30 Scott, Hari, Sharma (bib6) 2016; 22 Palumbo, Anderson (bib11) 2011; 364 Wang, Chang, Wong (bib42) 2011; 118 Liu, Sommermeyer, Cabanov, Kosasih, Hill, Riddell (bib41) 2016; 34 Sotillo (2019111521163035700_B49) 2015; 5 Turtle (2019111521163035700_B14) 2016; 8 Carpenter (2019111521163035700_B40) 2013; 19 Norelli (2019111521163035700_B62) 2018; 24 Hudecek (2019111521163035700_B37) 2013; 19 Maude (2019111521163035700_B13) 2014; 371 Ghermezi (2019111521163035700_B47) 2017; 102 Harousseau (2019111521163035700_B5) 1995; 13 Debeb (2019111521163035700_B52) 2012; 134 Attal (2019111521163035700_B1) 1996; 335 Scott (2019111521163035700_B6) 2016; 22 Gogishvili (2019111521163035700_B39) 2017; 130 Liu (2019111521163035700_B41) 2016; 34 Lonial (2019111521163035700_B9) 2015; 126 Golde (2019111521163035700_B34) 2013; 1828 O’Rourke (2019111521163035700_B31) 2017; 9 Rapoport (2019111521163035700_B50) 2015; 21 Massard (2019111521163035700_B46) 2018; 29 Sanchez (2019111521163035700_B58) 2016; 22 Varga (2019111521163035700_B57) 2018; 181 Sommermeyer (2019111521163035700_B43) 2017; 31 Eagar (2019111521163035700_B51) 2004; 20 Jelinek (2019111521163035700_B23) 2005; 8 Walker (2019111521163035700_B53) 2017; 25 Ramadoss (2019111521163035700_B55) 2015; 137 Kumar (2019111521163035700_B10) 2012; 26 Moreaux (2019111521163035700_B25) 2004; 103 Kalos (2019111521163035700_B15) 2011; 3 Raje (2019111521163035700_B29) 2019; 380 Giavridis (2019111521163035700_B61) 2018; 24 O’Connor (2019111521163035700_B19) 2004; 199 Brentjens (2019111521163035700_B12) 2013; 5 Barlogie (2019111521163035700_B2) 2006; 24 Chim (2019111521163035700_B8) 2018; 32 Watanabe (2019111521163035700_B48) 2015; 194 Novak (2019111521163035700_B24) 2004; 103 Wang (2019111521163035700_B42) 2011; 118 Riddell (2019111521163035700_B44) 1990; 128 Child (2019111521163035700_B4) 2003; 348 Brudno (2019111521163035700_B27) 2018; 36 Rennert (2019111521163035700_B22) 2000; 192 Ali (2019111521163035700_B26) 2016; 128 Laurent (2019111521163035700_B33) 2015; 6 Cohen (2019111521163035700_B28) 2019; 129 Salter (2019111521163035700_B36) 2018; 11 Tolcher (2019111521163035700_B59) 2012; 30 Thompson (2019111521163035700_B21) 2000; 192 Turtle (2019111521163035700_B16) 2017; 35 Seckinger (2019111521163035700_B20) 2017; 31 Grupp (2019111521163035700_B30) 2013; 368 Kochenderfer (2019111521163035700_B17) 2015; 33 Bladé (2019111521163035700_B3) 2010; 115 Pisklakova (2019111521163035700_B60) 2016; 17 Yuan (2019111521163035700_B35) 2015; 369 Lyu (2019111521163035700_B54) 2007; 6 Sonneveld (2019111521163035700_B7) 2016; 127 Palumbo (2019111521163035700_B11) 2011; 364 Fry (2019111521163035700_B32) 2018; 24 Tai (2019111521163035700_B56) 2014; 123 Hudecek (2019111521163035700_B38) 2015; 3 Avery (2019111521163035700_B18) 2003; 112 Salem (2019111521163035700_B45) 2018; 71 |
| References_xml | – volume: 22 start-page: 1893 year: 2016 end-page: 1899 ident: bib6 article-title: Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: a CIBMTR analysis publication-title: Biol Blood Marrow Transplant contributor: fullname: Sharma – volume: 192 start-page: 129 year: 2000 end-page: 135 ident: bib21 article-title: BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population publication-title: J Exp Med contributor: fullname: Kalled – volume: 9 year: 2017 ident: bib31 article-title: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma publication-title: Sci Transl Med contributor: fullname: Desai – volume: 20 start-page: 407 year: 2004 end-page: 415 ident: bib51 article-title: Notch 1 signaling regulates peripheral T cell activation publication-title: Immunity contributor: fullname: Bluestone – volume: 5 start-page: 1282 year: 2015 end-page: 1295 ident: bib49 article-title: Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy publication-title: Cancer Discov contributor: fullname: Black – volume: 6 start-page: 460 year: 2007 end-page: 470 ident: bib54 article-title: The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA publication-title: Mol Cancer Ther contributor: fullname: Rosenblum – volume: 348 start-page: 1875 year: 2003 end-page: 1883 ident: bib4 article-title: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma publication-title: N Engl J Med contributor: fullname: Medical Research Council Adult Leukaemia Working Party – volume: 130 start-page: 2838 year: 2017 end-page: 2847 ident: bib39 article-title: SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes publication-title: Blood contributor: fullname: Prommersberger – volume: 29 start-page: 1911 year: 2018 end-page: 1917 ident: bib46 article-title: First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer publication-title: Ann Oncol contributor: fullname: Soria – volume: 13 start-page: 132 year: 1995 end-page: 139 ident: bib5 article-title: Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma publication-title: Stem Cells contributor: fullname: Divine – volume: 30 start-page: 2348 year: 2012 end-page: 2353 ident: bib59 article-title: Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors publication-title: J Clin Oncol contributor: fullname: Mikulski – volume: 118 start-page: 1255 year: 2011 end-page: 1263 ident: bib42 article-title: A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells publication-title: Blood contributor: fullname: Wong – volume: 128 start-page: 189 year: 1990 end-page: 201 ident: bib44 article-title: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells publication-title: J Immunol Methods contributor: fullname: Greenberg – volume: 17 start-page: 477 year: 2016 end-page: 485 ident: bib60 article-title: Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment publication-title: Cancer Biol Ther contributor: fullname: Nefedova – volume: 335 start-page: 91 year: 1996 end-page: 97 ident: bib1 article-title: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome publication-title: N Engl J Med contributor: fullname: Stoppa – volume: 26 start-page: 149 year: 2012 end-page: 157 ident: bib10 article-title: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study [published correction appears in publication-title: Leukemia contributor: fullname: International Myeloma Working Group – volume: 8 start-page: 266 year: 2005 end-page: 288 ident: bib23 article-title: Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors publication-title: Curr Dir Autoimmun contributor: fullname: Darce – volume: 103 start-page: 3148 year: 2004 end-page: 3157 ident: bib25 article-title: BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone publication-title: Blood contributor: fullname: Jourdan – volume: 11 year: 2018 ident: bib36 article-title: Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function publication-title: Sci Signal contributor: fullname: Kennedy – volume: 199 start-page: 91 year: 2004 end-page: 98 ident: bib19 article-title: BCMA is essential for the survival of long-lived bone marrow plasma cells publication-title: J Exp Med contributor: fullname: Erickson – volume: 8 start-page: 355ra116 year: 2016 ident: bib14 article-title: Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells publication-title: Sci Transl Med contributor: fullname: Berger – volume: 3 start-page: 125 year: 2015 end-page: 135 ident: bib38 article-title: The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity publication-title: Cancer Immunol Res contributor: fullname: Kosasih – volume: 137 start-page: 5288 year: 2015 end-page: 5291 ident: bib55 article-title: An anti-B cell maturation antigen bispecific antibody for multiple myeloma publication-title: J Am Chem Soc contributor: fullname: Choi – volume: 24 start-page: 731 year: 2018 end-page: 738 ident: bib61 article-title: CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade publication-title: Nat Med contributor: fullname: Sadelain – volume: 24 start-page: 739 year: 2018 end-page: 748 ident: bib62 article-title: Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells publication-title: Nat Med contributor: fullname: Barbiera – volume: 181 start-page: 433 year: 2018 end-page: 446 ident: bib57 article-title: Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma publication-title: Br J Haematol contributor: fullname: Richardson – volume: 24 start-page: 929 year: 2006 end-page: 936 ident: bib2 article-title: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 [published correction appears in publication-title: J Clin Oncol contributor: fullname: Anderson – volume: 36 start-page: 2267 year: 2018 end-page: 2280 ident: bib27 article-title: T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma publication-title: J Clin Oncol contributor: fullname: Hartman – volume: 31 start-page: 2191 year: 2017 end-page: 2199 ident: bib43 article-title: Fully human CD19-specific chimeric antigen receptors for T-cell therapy publication-title: Leukemia contributor: fullname: Shamah – volume: 112 start-page: 286 year: 2003 end-page: 297 ident: bib18 article-title: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells publication-title: J Clin Invest contributor: fullname: Ellyard – volume: 192 start-page: 1677 year: 2000 end-page: 1684 ident: bib22 article-title: A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth publication-title: J Exp Med contributor: fullname: Cachero – volume: 371 start-page: 1507 year: 2014 end-page: 1517 ident: bib13 article-title: Chimeric antigen receptor T cells for sustained remissions in leukemia publication-title: N Engl J Med contributor: fullname: Shaw – volume: 31 start-page: 396 year: 2017 end-page: 410 ident: bib20 article-title: Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment publication-title: Cancer Cell contributor: fullname: Moser – volume: 128 start-page: 1688 year: 2016 end-page: 1700 ident: bib26 article-title: T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma publication-title: Blood contributor: fullname: Maric – volume: 380 start-page: 1726 year: 2019 end-page: 1737 ident: bib29 article-title: Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma publication-title: N Engl J Med contributor: fullname: Lin – volume: 102 start-page: 785 year: 2017 end-page: 795 ident: bib47 article-title: Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients publication-title: Haematologica contributor: fullname: Vardanyan – volume: 103 start-page: 689 year: 2004 end-page: 694 ident: bib24 article-title: Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival publication-title: Blood contributor: fullname: Arendt – volume: 33 start-page: 540 year: 2015 end-page: 549 ident: bib17 article-title: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor publication-title: J Clin Oncol contributor: fullname: Kassim – volume: 194 start-page: 911 year: 2015 end-page: 920 ident: bib48 article-title: Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells publication-title: J Immunol contributor: fullname: Martens – volume: 115 start-page: 3655 year: 2010 end-page: 3663 ident: bib3 article-title: Hematopoietic stem cell transplantation for multiple myeloma beyond 2010 publication-title: Blood contributor: fullname: Carreras – volume: 129 start-page: 2210 year: 2019 end-page: 2221 ident: bib28 article-title: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma publication-title: J Clin Invest contributor: fullname: Stadtmauer – volume: 123 start-page: 3128 year: 2014 end-page: 3138 ident: bib56 article-title: Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma publication-title: Blood contributor: fullname: Acharya – volume: 71 start-page: 106 year: 2018 end-page: 111 ident: bib45 article-title: Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in myeloma publication-title: Leuk Res contributor: fullname: Yuan – volume: 368 start-page: 1509 year: 2013 end-page: 1518 ident: bib30 article-title: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia publication-title: N Engl J Med contributor: fullname: Barrett – volume: 34 start-page: 430 year: 2016 end-page: 434 ident: bib41 article-title: Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy publication-title: Nat Biotechnol contributor: fullname: Riddell – volume: 369 start-page: 20 year: 2015 end-page: 27 ident: bib35 article-title: Notch signaling: an emerging therapeutic target for cancer treatment publication-title: Cancer Lett contributor: fullname: Xu – volume: 25 start-page: 2189 year: 2017 end-page: 2201 ident: bib53 article-title: Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase publication-title: Mol Ther contributor: fullname: Zhang – volume: 19 start-page: 2048 year: 2013 end-page: 2060 ident: bib40 article-title: B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma publication-title: Clin Cancer Res contributor: fullname: Pittaluga – volume: 134 start-page: 495 year: 2012 end-page: 510 ident: bib52 article-title: Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells publication-title: Breast Cancer Res Treat contributor: fullname: Boley – volume: 126 start-page: 1536 year: 2015 end-page: 1543 ident: bib9 article-title: How I treat high-risk myeloma publication-title: Blood contributor: fullname: Kaufman – volume: 24 start-page: 20 year: 2018 end-page: 28 ident: bib32 article-title: CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy publication-title: Nat Med contributor: fullname: Orentas – volume: 3 start-page: 95ra73 year: 2011 ident: bib15 article-title: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia publication-title: Sci Transl Med contributor: fullname: Porter – volume: 19 start-page: 3153 year: 2013 end-page: 3164 ident: bib37 article-title: Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells publication-title: Clin Cancer Res contributor: fullname: Kosasih – volume: 5 start-page: 177ra38 year: 2013 ident: bib12 article-title: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia publication-title: Sci Transl Med contributor: fullname: Riviere – volume: 364 start-page: 1046 year: 2011 end-page: 1060 ident: bib11 article-title: Multiple myeloma publication-title: N Engl J Med contributor: fullname: Anderson – volume: 6 start-page: 7333 year: 2015 ident: bib33 article-title: γ-Secretase directly sheds the survival receptor BCMA from plasma cells publication-title: Nat Commun contributor: fullname: Kuhn – volume: 1828 start-page: 2898 year: 2013 end-page: 2907 ident: bib34 article-title: γ-Secretase inhibitors and modulators publication-title: Biochim Biophys Acta contributor: fullname: Miele – volume: 21 start-page: 914 year: 2015 end-page: 921 ident: bib50 article-title: NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma publication-title: Nat Med contributor: fullname: Binder-Scholl – volume: 22 start-page: 3383 year: 2016 end-page: 3397 ident: bib58 article-title: Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma publication-title: Clin Cancer Res contributor: fullname: Tang – volume: 32 start-page: 252 year: 2018 end-page: 262 ident: bib8 article-title: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond [published correction appears in publication-title: Leukemia contributor: fullname: Orlowski – volume: 127 start-page: 2955 year: 2016 end-page: 2962 ident: bib7 article-title: Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group publication-title: Blood contributor: fullname: Lonial – volume: 35 start-page: 3010 year: 2017 end-page: 3020 ident: bib16 article-title: Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib publication-title: J Clin Oncol contributor: fullname: Hanafi – volume: 369 start-page: 20 issue: 1 year: 2015 ident: 2019111521163035700_B35 article-title: Notch signaling: an emerging therapeutic target for cancer treatment publication-title: Cancer Lett doi: 10.1016/j.canlet.2015.07.048 contributor: fullname: Yuan – volume: 3 start-page: 125 issue: 2 year: 2015 ident: 2019111521163035700_B38 article-title: The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-14-0127 contributor: fullname: Hudecek – volume: 6 start-page: 7333 year: 2015 ident: 2019111521163035700_B33 article-title: γ-Secretase directly sheds the survival receptor BCMA from plasma cells publication-title: Nat Commun doi: 10.1038/ncomms8333 contributor: fullname: Laurent – volume: 5 start-page: 1282 issue: 12 year: 2015 ident: 2019111521163035700_B49 article-title: Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-15-1020 contributor: fullname: Sotillo – volume: 127 start-page: 2955 issue: 24 year: 2016 ident: 2019111521163035700_B7 article-title: Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group publication-title: Blood doi: 10.1182/blood-2016-01-631200 contributor: fullname: Sonneveld – volume: 118 start-page: 1255 issue: 5 year: 2011 ident: 2019111521163035700_B42 article-title: A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells publication-title: Blood doi: 10.1182/blood-2011-02-337360 contributor: fullname: Wang – volume: 30 start-page: 2348 issue: 19 year: 2012 ident: 2019111521163035700_B59 article-title: Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors publication-title: J Clin Oncol doi: 10.1200/JCO.2011.36.8282 contributor: fullname: Tolcher – volume: 1828 start-page: 2898 issue: 12 year: 2013 ident: 2019111521163035700_B34 article-title: γ-Secretase inhibitors and modulators publication-title: Biochim Biophys Acta doi: 10.1016/j.bbamem.2013.06.005 contributor: fullname: Golde – volume: 25 start-page: 2189 issue: 9 year: 2017 ident: 2019111521163035700_B53 article-title: Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase publication-title: Mol Ther doi: 10.1016/j.ymthe.2017.06.008 contributor: fullname: Walker – volume: 123 start-page: 3128 issue: 20 year: 2014 ident: 2019111521163035700_B56 article-title: Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma publication-title: Blood doi: 10.1182/blood-2013-10-535088 contributor: fullname: Tai – volume: 11 issue: 544 year: 2018 ident: 2019111521163035700_B36 article-title: Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function publication-title: Sci Signal doi: 10.1126/scisignal.aat6753 contributor: fullname: Salter – volume: 126 start-page: 1536 issue: 13 year: 2015 ident: 2019111521163035700_B9 article-title: How I treat high-risk myeloma publication-title: Blood doi: 10.1182/blood-2015-06-653261 contributor: fullname: Lonial – volume: 364 start-page: 1046 issue: 11 year: 2011 ident: 2019111521163035700_B11 article-title: Multiple myeloma publication-title: N Engl J Med doi: 10.1056/NEJMra1011442 contributor: fullname: Palumbo – volume: 20 start-page: 407 issue: 4 year: 2004 ident: 2019111521163035700_B51 article-title: Notch 1 signaling regulates peripheral T cell activation publication-title: Immunity doi: 10.1016/S1074-7613(04)00081-0 contributor: fullname: Eagar – volume: 36 start-page: 2267 issue: 22 year: 2018 ident: 2019111521163035700_B27 article-title: T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma publication-title: J Clin Oncol doi: 10.1200/JCO.2018.77.8084 contributor: fullname: Brudno – volume: 102 start-page: 785 issue: 4 year: 2017 ident: 2019111521163035700_B47 article-title: Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients publication-title: Haematologica doi: 10.3324/haematol.2016.150896 contributor: fullname: Ghermezi – volume: 115 start-page: 3655 issue: 18 year: 2010 ident: 2019111521163035700_B3 article-title: Hematopoietic stem cell transplantation for multiple myeloma beyond 2010 publication-title: Blood doi: 10.1182/blood-2009-08-238196 contributor: fullname: Bladé – volume: 137 start-page: 5288 issue: 16 year: 2015 ident: 2019111521163035700_B55 article-title: An anti-B cell maturation antigen bispecific antibody for multiple myeloma publication-title: J Am Chem Soc doi: 10.1021/jacs.5b01876 contributor: fullname: Ramadoss – volume: 128 start-page: 189 issue: 2 year: 1990 ident: 2019111521163035700_B44 article-title: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells publication-title: J Immunol Methods doi: 10.1016/0022-1759(90)90210-M contributor: fullname: Riddell – volume: 192 start-page: 129 issue: 1 year: 2000 ident: 2019111521163035700_B21 article-title: BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population publication-title: J Exp Med doi: 10.1084/jem.192.1.129 contributor: fullname: Thompson – volume: 6 start-page: 460 issue: 2 year: 2007 ident: 2019111521163035700_B54 article-title: The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-06-0254 contributor: fullname: Lyu – volume: 181 start-page: 433 issue: 4 year: 2018 ident: 2019111521163035700_B57 article-title: Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma publication-title: Br J Haematol doi: 10.1111/bjh.15116 contributor: fullname: Varga – volume: 368 start-page: 1509 issue: 16 year: 2013 ident: 2019111521163035700_B30 article-title: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1215134 contributor: fullname: Grupp – volume: 192 start-page: 1677 issue: 11 year: 2000 ident: 2019111521163035700_B22 article-title: A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth publication-title: J Exp Med doi: 10.1084/jem.192.11.1677 contributor: fullname: Rennert – volume: 103 start-page: 3148 issue: 8 year: 2004 ident: 2019111521163035700_B25 article-title: BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone publication-title: Blood doi: 10.1182/blood-2003-06-1984 contributor: fullname: Moreaux – volume: 29 start-page: 1911 issue: 9 year: 2018 ident: 2019111521163035700_B46 article-title: First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdy244 contributor: fullname: Massard – volume: 21 start-page: 914 issue: 8 year: 2015 ident: 2019111521163035700_B50 article-title: NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma publication-title: Nat Med doi: 10.1038/nm.3910 contributor: fullname: Rapoport – volume: 13 start-page: 132 issue: suppl 2 year: 1995 ident: 2019111521163035700_B5 article-title: Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma publication-title: Stem Cells contributor: fullname: Harousseau – volume: 26 start-page: 149 issue: 1 year: 2012 ident: 2019111521163035700_B10 article-title: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study [published correction appears in Leukemia. 2012;26(5):1153] publication-title: Leukemia doi: 10.1038/leu.2011.196 contributor: fullname: Kumar – volume: 5 start-page: 177ra38 issue: 177 year: 2013 ident: 2019111521163035700_B12 article-title: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3005930 contributor: fullname: Brentjens – volume: 31 start-page: 396 issue: 3 year: 2017 ident: 2019111521163035700_B20 article-title: Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.02.002 contributor: fullname: Seckinger – volume: 24 start-page: 929 issue: 6 year: 2006 ident: 2019111521163035700_B2 article-title: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 [published correction appears in J Clin Oncol. 2006;24(17):2687] publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.5807 contributor: fullname: Barlogie – volume: 22 start-page: 3383 issue: 13 year: 2016 ident: 2019111521163035700_B58 article-title: Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-2224 contributor: fullname: Sanchez – volume: 35 start-page: 3010 issue: 26 year: 2017 ident: 2019111521163035700_B16 article-title: Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib publication-title: J Clin Oncol doi: 10.1200/JCO.2017.72.8519 contributor: fullname: Turtle – volume: 128 start-page: 1688 issue: 13 year: 2016 ident: 2019111521163035700_B26 article-title: T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma publication-title: Blood doi: 10.1182/blood-2016-04-711903 contributor: fullname: Ali – volume: 129 start-page: 2210 issue: 6 year: 2019 ident: 2019111521163035700_B28 article-title: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma publication-title: J Clin Invest doi: 10.1172/JCI126397 contributor: fullname: Cohen – volume: 348 start-page: 1875 issue: 19 year: 2003 ident: 2019111521163035700_B4 article-title: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma publication-title: N Engl J Med doi: 10.1056/NEJMoa022340 contributor: fullname: Child – volume: 130 start-page: 2838 issue: 26 year: 2017 ident: 2019111521163035700_B39 article-title: SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes publication-title: Blood doi: 10.1182/blood-2017-04-778423 contributor: fullname: Gogishvili – volume: 134 start-page: 495 issue: 2 year: 2012 ident: 2019111521163035700_B52 article-title: Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-012-2075-8 contributor: fullname: Debeb – volume: 9 issue: 399 year: 2017 ident: 2019111521163035700_B31 article-title: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaa0984 contributor: fullname: O’Rourke – volume: 335 start-page: 91 issue: 2 year: 1996 ident: 2019111521163035700_B1 article-title: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome publication-title: N Engl J Med doi: 10.1056/NEJM199607113350204 contributor: fullname: Attal – volume: 199 start-page: 91 issue: 1 year: 2004 ident: 2019111521163035700_B19 article-title: BCMA is essential for the survival of long-lived bone marrow plasma cells publication-title: J Exp Med doi: 10.1084/jem.20031330 contributor: fullname: O’Connor – volume: 103 start-page: 689 issue: 2 year: 2004 ident: 2019111521163035700_B24 article-title: Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival publication-title: Blood doi: 10.1182/blood-2003-06-2043 contributor: fullname: Novak – volume: 24 start-page: 731 issue: 6 year: 2018 ident: 2019111521163035700_B61 article-title: CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade publication-title: Nat Med doi: 10.1038/s41591-018-0041-7 contributor: fullname: Giavridis – volume: 34 start-page: 430 issue: 4 year: 2016 ident: 2019111521163035700_B41 article-title: Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy publication-title: Nat Biotechnol doi: 10.1038/nbt.3461 contributor: fullname: Liu – volume: 31 start-page: 2191 issue: 10 year: 2017 ident: 2019111521163035700_B43 article-title: Fully human CD19-specific chimeric antigen receptors for T-cell therapy publication-title: Leukemia doi: 10.1038/leu.2017.57 contributor: fullname: Sommermeyer – volume: 22 start-page: 1893 issue: 10 year: 2016 ident: 2019111521163035700_B6 article-title: Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: a CIBMTR analysis publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2016.07.007 contributor: fullname: Scott – volume: 17 start-page: 477 issue: 5 year: 2016 ident: 2019111521163035700_B60 article-title: Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment publication-title: Cancer Biol Ther doi: 10.1080/15384047.2016.1156261 contributor: fullname: Pisklakova – volume: 3 start-page: 95ra73 issue: 95 year: 2011 ident: 2019111521163035700_B15 article-title: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3002842 contributor: fullname: Kalos – volume: 19 start-page: 2048 issue: 8 year: 2013 ident: 2019111521163035700_B40 article-title: B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-2422 contributor: fullname: Carpenter – volume: 112 start-page: 286 issue: 2 year: 2003 ident: 2019111521163035700_B18 article-title: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells publication-title: J Clin Invest doi: 10.1172/JCI18025 contributor: fullname: Avery – volume: 380 start-page: 1726 issue: 18 year: 2019 ident: 2019111521163035700_B29 article-title: Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma publication-title: N Engl J Med doi: 10.1056/NEJMoa1817226 contributor: fullname: Raje – volume: 33 start-page: 540 issue: 6 year: 2015 ident: 2019111521163035700_B17 article-title: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor publication-title: J Clin Oncol doi: 10.1200/JCO.2014.56.2025 contributor: fullname: Kochenderfer – volume: 8 start-page: 355ra116 issue: 355 year: 2016 ident: 2019111521163035700_B14 article-title: Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaf8621 contributor: fullname: Turtle – volume: 71 start-page: 106 year: 2018 ident: 2019111521163035700_B45 article-title: Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in myeloma publication-title: Leuk Res doi: 10.1016/j.leukres.2018.07.015 contributor: fullname: Salem – volume: 24 start-page: 739 issue: 6 year: 2018 ident: 2019111521163035700_B62 article-title: Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells publication-title: Nat Med doi: 10.1038/s41591-018-0036-4 contributor: fullname: Norelli – volume: 19 start-page: 3153 issue: 12 year: 2013 ident: 2019111521163035700_B37 article-title: Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-0330 contributor: fullname: Hudecek – volume: 8 start-page: 266 year: 2005 ident: 2019111521163035700_B23 article-title: Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors publication-title: Curr Dir Autoimmun doi: 10.1159/000082107 contributor: fullname: Jelinek – volume: 32 start-page: 252 issue: 2 year: 2018 ident: 2019111521163035700_B8 article-title: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond [published correction appears in Leukemia. 2019;33(4):1058-1059] publication-title: Leukemia doi: 10.1038/leu.2017.329 contributor: fullname: Chim – volume: 371 start-page: 1507 issue: 16 year: 2014 ident: 2019111521163035700_B13 article-title: Chimeric antigen receptor T cells for sustained remissions in leukemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1407222 contributor: fullname: Maude – volume: 24 start-page: 20 issue: 1 year: 2018 ident: 2019111521163035700_B32 article-title: CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy publication-title: Nat Med doi: 10.1038/nm.4441 contributor: fullname: Fry – volume: 194 start-page: 911 issue: 3 year: 2015 ident: 2019111521163035700_B48 article-title: Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells publication-title: J Immunol doi: 10.4049/jimmunol.1402346 contributor: fullname: Watanabe |
| SSID | ssj0014325 |
| Score | 2.6778293 |
| Snippet | B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Despite promising objective... Despite notably high response rates to B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells in multiple myeloma, few patients have a... Small-molecule GSIs increase BCMA surface expression on myeloma cells, resulting in enhanced CAR T-cell efficacy. B-cell maturation antigen (BCMA) is a... |
| SourceID | pubmedcentral proquest crossref pubmed elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 1585 |
| SubjectTerms | Amyloid Precursor Protein Secretases - antagonists & inhibitors Animals B-Cell Maturation Antigen - metabolism Benzazepines - pharmacology Clinical Trials as Topic Humans Immunobiology and Immunotherapy Immunotherapy, Adoptive - methods Mice Mice, Inbred NOD Mice, SCID Multiple Myeloma - therapy Receptors, Chimeric Antigen Xenograft Model Antitumor Assays |
| Title | γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma |
| URI | https://dx.doi.org/10.1182/blood.2019000050 https://www.ncbi.nlm.nih.gov/pubmed/31558469 https://www.proquest.com/docview/2299136309/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC6871311 |
| Volume | 134 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEB4tXfG4IOjyKC8ZCSFxiBrbSewc24rVCigXdtHeIttx1EjbtNDuob-L_8FvYsZJCgXEgZsdx5E1M_LMZL6ZAXjluHEoSDbSRpRRkkkX2URVkecKDeY8FXEomT__mJ1dJO8u08sjmPW5MASr7O7-9k4Pt3X3ZNxRc7yua8rxRXWaKy4o2JTL9AYcC5XFYgDHk-nn9x_2wYREiraRATrPtKGPVmoxDuhwAnhR78yYku__rp3-tD5_B1H-opVO78Hdzpxkk_bE9-HIN0M4mTToSi937DULAM_w53wIN6f96Pasb_M2hFvzLrp-Al--f4s-kRm5RdXG6mZR2wDowiHZlhu_YZ4qThi3Y6uKTWfzSUSZmoQ2Ym5Rh-APQ1ZRhU-GZPVr9OjZOaPowAa_wnr4Ilvu_NVqaR7Axenb89lZ1LVkiBxqsW0kbJmrlMqbpqVW0mr0f3TqpLOEBYvzUnKL_q1KTMJVZT2nwknSVMZXVnqcPoRBs2r8Y2DC6FzHmc1FhS6gszTFC0FXpeFlxf0I3vSsKNZt5Y0ieCxaFIFtxU-2jUD2vCoOpKdAxfCPXS97thZIdKKFafzqelMIVNJcZjLOR_CoZfP-DBItMDTacEUdCMD-BSrYfbjS1ItQuDtD71Ry_uS_TvsU7tAk5EGqZzDYfr32z9Eg2toXncD_AHWAClY |
| link.rule.ids | 230,315,786,790,891,27602,27957,27958,45698 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwEB4tXcFyWUGXhbL8GAkhcYga2_lxjm21q8K2e6GL9hbZiaNGommh3UOfi_fgmZhxkkJZxIGbHceRNWN5vsl8MwZ4m3Gd4UYyntIi94JIZp4J4sKzPEbAnITCdyXzp1fR-Dr4eBPeHMCozYUhWmVz9tdnujutmyf9Rpr9VVlSji-a0yTmgoJNiQzvwSGigUR14HAw_Hw52QUTAinqiwzQeaYJbbRSib5jhxPBi-7O9Cn5_u_W6S76_JNE-ZtVungExw2cZIN6xY_hwFZdOBlU6EovtuwdcwRP9-e8C_eHbeto1F7z1oUH0ya6fgJff3z3PhGM3KBpY2U1L40jdGGTsOXarpmlihM627JlwYaj6cCjTE1iG7FsXrrgD0NVUYVPhmK1K_To2YxRdGCNX2EtfZEttvbLcqGfwPXF-Ww09porGbwMrdjGEyZP4pDKm4a5iqVR6P-oMJOZIS6Yn-SSG_Rv40AHPC6M5VQ4SepC28JIi91T6FTLyj4DJrRKlB-ZRBToAmaGunggqCLXPC-47cH7VhXpqq68kTqPRYnUqS39pbYeyFZX6d7uSdEw_GPWm1atKQqdZKEru7xdpwKNNJeR9JMePK3VvFuDRASGoA1H4r0NsHuBCnbvj1Tl3BXujtA7lZw__6_Vvoaj8Ww6SScfri7P4CENuJzI-AV0Nt9u7UsERxvzqtn8PwE-Xg1P |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%CE%B3-Secretase+inhibition+increases+efficacy+of+BCMA-specific+chimeric+antigen+receptor+T+cells+in+multiple+myeloma&rft.jtitle=Blood&rft.au=Pont%2C+Margot+J&rft.au=Hill%2C+Tyler&rft.au=Cole%2C+Gabriel+O&rft.au=Abbott%2C+Joe+J&rft.date=2019-11-07&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=134&rft.issue=19&rft.spage=1585&rft_id=info:doi/10.1182%2Fblood.2019000050&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |